Neonatal diabetes due to homozygous INS gene promoter mutations: Highly variable phenotype, remission and early relapse during the first 3 years of life

2020 ◽  
Vol 21 (7) ◽  
pp. 1169-1175
Author(s):  
Meliha Demiral ◽  
Huseyin Demirbilek ◽  
Kıymet Çelik ◽  
Nilufer Okur ◽  
Khalid Hussain ◽  
...  
Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1570-1570
Author(s):  
Caterina Matteucci ◽  
Tamara Iannotti ◽  
Lucia Brandimarte ◽  
Valeria Nofrini ◽  
Gianluca Barba ◽  
...  

Abstract Mutations at the protein-coding region of TERT gene (chromosome 5p15.33) have been well characterized in patients affected by a constitutional telomere syndrome, including diskeratosis, aplastic anemia and pulmonary fibrosis (Calado RT, Hematology, ASH 2009:338). In rare cases somatic mutations may occur in de novo MDS/AML (Calado RT, Young NS. Blood 2008;111:4446). Mutations involving the regulatory region of TERT gene have been recently identified in a consistent proportion of familial and sporadic melanoma and in a subset of tumors originating from tissues with low rate of self-renewal (glioblastoma, liposarcoma, oligodendroglioma bladder cancer, upper urinary tract cancer). These mutations create new binding motifs for Ets/TCF transcription factors, thus increasing TERT gene transcription (Killela PJ et al, PNAS 2013;110:6021; Horn S et al, Science 2013;339:959). As far as we know TERT promoter mutations were never described in MDS. Material and Methods Index Case. A 52 years old woman was selected because of a complex phenotype including abnormal skin pigmentation, familial pulmonary fibrosis, osteoarthritis, and a refractory cytopenia with multilineage dysplasia (RCMD, WHO 2008) with a 47,XX,+8 karyotype. Screening Cases. Mutational analysis was extended to a cohort of 115 patients (72 males; 44 females, median age 69) referred to the Laboratory of Cytogenetics, Hematology Department,University of Perugia, Italy. Cytogenetics was normal in 49 cases (43%). Abnormalities included: isolated del(5q) (seven cases, 6%); del(5q) plus one additional change (three cases, 3%); isolated del(20q) (fourteen cases, 12%); trisomy 8 (five cases, 4%); monosomy 7 (two cases, 2%); -Y (three cases, 3%); del(11q) (two cases, 2%); complex karyotype (twenty-four cases, 21%); other aberrations (six cases, 5%). Genomic DNA was extracted from bone marrow (BM) of all cases and from peripheral blood T lymphocytes of index case using Salting out method. In all cases TERT promoter was screened using PCR based DHPLC assay (Wave system; MD Transgenomic Inc. Omaha, NE). The 274bp amplicon was amplified with forward primer 5'GTCCTGCCCCTTCACCTTC3' and reverse primer 5'AGCACCTCGCGGTAGTGG3' using Robust Start Taq KAPA2G (Biosystems, Woburn, MA). DNA from abnormal elution profiles were re-amplified and sequenced by Sanger method (ABI 3500 Genetic Analyzer, Applied Biosystems). Variations were detected using Finch TV v. 1.4.0. In the index case 23 amplicons encompassing all 16 exons of TERT gene were also screened (NC_000005.9). Mutations cloning was carried out after RNA extraction (Trizol, Invitrogen, Life Technologies, Paisley, UK), reverse transcription (ThermoscriptTM RT-PCR System, Invitrogen) and amplification (TERT_2CF (5'-CAGCGCTACTGGCAAATGCG-3' Ta-61,4°C; and TERT_2543R (5'-GGCACTGGACGTAGGACTTG-3' Ta-61,4°C). PCR products were sub-cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and sequenced. Results Index Case. Patient was a compound heterozygous for two germline variations: a nonsense mutation c.1209C>A p.C403* (exon 2) and a missense mutation c.2455C>T p.R819C (exon 8). A putative somatic A>C transition 57 bp before the ATG start codon was detected only in BM cells (Table). Screening Cases. DHPLC analysis showed three patients (2.6%) with a two-peak elution profile. Sequencing revealed a 10 bp duplication (c.1-110_1-101) in case 2; a c.1-124 C>T point mutation in case 3; a point mutation c.1-78 C>T in case 4 (Table). Comment We showed that TERT gene promoter variations are recurrent events in 2.6% of MDS patients. Only low/int1 risk MDS (IPSS) were affected in this series. The c.1-57A>C, previously reported as a germline activating variation in familial melanoma (Horn S et al, Science 2013;339:959), was likely a somatic mutation in our index case, thus supporting its role in clonal MDS proliferation. We first found the melanoma activating c.1-124 C>T point mutation (Huang FW et al, Science 2013;339:957; Killela PJ et al, PNAS 2013;110:6021) in a MDS with isolated del(5q). The new variation of our case n.4 does not appear to introduce a new transcription factor binding site (http://www.cbrc.jp/research/db/TFSEARCH.html), whereas the 10bp duplication of case 2 indicates an hypothetical binding site for Ikaros. Further results from ongoing functional studies in these cases will be presented. Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
Vol 99 (1) ◽  
pp. 100-103 ◽  
Author(s):  
Aleksandra Nikolic ◽  
Momcilo Ristanovic ◽  
Vladan Zivaljevic ◽  
Aleksandra Divac Rankov ◽  
Dragica Radojkovic ◽  
...  

1989 ◽  
Vol 10 (6) ◽  
pp. 412-424 ◽  
Author(s):  
Thomas D. Sullivan ◽  
John W. Schiefelbein ◽  
Oliver E. Nelson

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1624
Author(s):  
Marta Mellai ◽  
Omar Porrini Prandini ◽  
Aurora Mustaccia ◽  
Valentina Fogazzi ◽  
Marta Allesina ◽  
...  

Background: The role of telomerase reverse transcriptase (TERT) gene promoter mutations (pTERT) in atypical and anaplastic meningiomas remains controversial. This study aimed to evaluate their impact on the histologic diagnosis and prognosis in a retrospective series of 74 patients with atypical and anaplastic meningioma, including disease progression and relapse. A supplementary panel of 21 benign tumours was used as a control cohort. Materials and Methods: The mutation rate of the pTERT gene was assessed by Sanger sequencing. ATRX protein expression was detected by immunohistochemistry. The phenotypic and genotypic intra-tumour heterogeneity was studied in a sub-group of 12 cases using a Molecular Machines & Industries (MMI) CellCut laser microdissection (LMD) system. Results: pTERT mutations were detected in 12/74 (17.6%) malignant meningiomas. The mutation rate was significantly higher in anaplastic meningiomas (7/23, 30.4%) compared to atypical tumours (5/48, 10.4%) (p = 0.0443). In contrast, the mutation rate was < 5% in benign tumours. All pTERT mutant cases retained nuclear ATRX immunoreactivity. pTERT mutations were significantly associated with the histologic grade (p = 0.0443) and were adverse prognostic factors for anaplastic tumours (p = 0.06). Conclusion: We reported on the pTERT mutation spectrum in malignant meningiomas, supporting their use in the prognostic classification.


Hemoglobin ◽  
2007 ◽  
Vol 31 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Barry Eng ◽  
Lynda Walker ◽  
Lisa M. Nakamura ◽  
Carolyn Hoppe ◽  
Mahin Azimi ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1225-1225
Author(s):  
Man Yu ◽  
Xin Ye ◽  
Hemei Han ◽  
Mary Stafford ◽  
Patrick A. Navas ◽  
...  

Abstract Non-deletional HPFHs are g gene promoter mutations, which are associated with HbF elevation in heterozygous adult individuals. To investigate the mechanism whereby these mutations result in g gene activation, the −198 (T→C) and −175 (T→C) mutations were introduced into the promoter of the Ag gene in the context of a 213 kb b-globin locus YAC. The mutated YAC DNA was then used to produce transgenic mice. Expression of the human g and b globin gene was examined by RNase protection assay in blood of the adult transgenic mice carrying either −198 or −175 mutations. The level of g gene expression ranged from 4.0 to 8.5% of the human b mRNA in the −198 mutant transgenic mice, and from 25 to 41% in the −175 mutant mice. In contrast, there was no detectable level of g gene expression in the blood of wild type transgenic mice. The ratios of g/b mRNA in the mutant transgenic mice correspond to the levels of Hb F in adult individuals carrying the corresponding mutations: Hb F in heterozygotes for HPFH −198 and −175 mutations ranges from 3.5 to 10% and from 36 to 41%, respectively. To delineate the mechanism of g gene reactivation by the HPFH mutations, the CACCC box in the g gene promoter was deleted in the context of the mutant YAC. In contrast to the −175 HPFH bYAC mice, in the doubly mutated −175 HPFH DAgCACCC bYAC mice, expression of the g gene in the adult blood of the transgenic mice was undetectable. These results provide strong evidence that an intact CACCC box is required for g gene activation in the −175 HPFH mutation. We conclude that YAC mice can faithfully reproduce the phenotypes of nondeletional HPFH mutations and be used for the investigation of the mechanisms by which these mutations activate the g gene.


2020 ◽  
Author(s):  
Ildem Akerman ◽  
Miguel Angel Maestro ◽  
Vane Grau ◽  
Javier García-Hurtado ◽  
Gerhard Mittler ◽  
...  

ABSTRACTDespite the central role of chromosomal context in gene transcription, human noncoding DNA variants are generally studied outside of their endogenous genomic location. This poses major limitations to understand the true consequences of causal regulatory variants. We focused on a cis-regulatory mutation (c.-331C>G) in the INS gene promoter that is recurrently mutated in unrelated patients with recessive neonatal diabetes. We created mice in which a ~3.1 kb human INS upstream region carrying −331C or −331G alleles replaced the orthologous mouse Ins2 region. This human sequence drove cell-specific transcription in mice. It also recapitulated poised chromatin during pancreas development and active chromatin in differentiated β-cells. The c.-331C>G mutation, however, blocked active chromatin formation in differentiated b-cells. We further show that another neonatal diabetes gene product, GLIS3, had a singular pioneer-like ability to activate INS chromatin in non-pancreatic cells, which was hampered by the c.-331C>G mutation. This in vivo analysis of human regulatory defects, therefore, uncovered cis and trans components of a mechanism that is essential to activate the endogenous INS gene.


2009 ◽  
Vol 55 (4) ◽  
pp. 698-708 ◽  
Author(s):  
Karen M K de Vooght ◽  
Richard van Wijk ◽  
Wouter W van Solinge

Abstract Background: Although promoter mutations are known to cause functionally important consequences for gene expression, promoter analysis is not a regular part of DNA diagnostics. Content: This review covers different important aspects of promoter mutation analysis and includes a proposed model procedure for studying promoter mutations. Characterization of a promoter sequence variation includes a comprehensive study of the literature and databases of human mutations and transcription factors. Phylogenetic footprinting is also used to evaluate the putative importance of the promoter region of interest. This in silico analysis is, in general, followed by in vitro functional assays, of which transient and stable transfection assays are considered the gold-standard methods. Electrophoretic mobility shift and supershift assays are used to identify trans-acting proteins that putatively interact with the promoter region of interest. Finally, chromatin immunoprecipitation assays are essential to confirm in vivo binding of these proteins to the promoter. Summary: Although promoter mutation analysis is complex, often laborious, and difficult to perform, it is an essential part of the diagnosis of disease-causing promoter mutations and improves our understanding of the role of transcriptional regulation in human disease. We recommend that routine laboratories and research groups specialized in gene promoter research cooperate to expand general knowledge and diagnosis of gene-promoter defects.


Sign in / Sign up

Export Citation Format

Share Document